Effect of benazepril combined with losartan on renal function in the patients with early diabetic nephropathy

Objective To investigate the effect of angiotension converting enzyme inhibitors and angiotensin Ⅱ receptor blocker on the renal function of the patients with early diabetic nephropathy. Methods Seventy-six patients with diabetic nephropathy were randomly divided into four groups included 19 patients each. Diabetic mellitus group received neither benazepril nor losartan, benazepril group received benazepril only, losartan group received losartan alone and benazepril losartan group received benazepril combined with losartan. Another 19 healthy persons was as normal controls. 24-hour urine microamount albumin, serum creatinine and plasminogen activator inhibitor-1 were detected before and after 2 months treatment. Results The level of serum creatinine and plasminogen activator inhibitor-1 in benazepril losartan group was lowered significantly compared with that of diabetic mellitus group (P0.05). The level of microamount albumin in benazepril losartan group was also notable degraded compared with the normal control(P0.01), the diabetic mellitus group1(P0.01), the benazepril group (P0.05) and the losartan group(P0.05). Conclusion benazepril and losartan combination therapy have a better effect on decreasing microamount albumin, serum creatinine and plasminogen activator inhibitor-1 than Benazepril or losartan therapy alone. It may delay or even prevent the development of early diabetic nephropathy.